NASDAQ: SGMTSagimet Biosciences Inc Stock
$3.63-0.41 (-10.15%)
Updated Dec 8, 2023
SGMT Price
$3.63
Fair Value Price
N/A
Market Cap
$77.59M
52 Week Low
$2.13
52 Week High
$18.33
P/E
N/A
P/B
0.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
N/A
Beta
2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGMT Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGMT is good value based on its book value relative to its share price (0.79x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
SGMT's short-term assets ($102.82M) exceed its short-term liabilities ($5.05M)
Short-term Liabilities Financials
SGMT's short-term assets ($102.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more SGMT due diligence checks available for Premium users.
Be the first to know about important SGMT news, forecast changes, insider trades & much more!
SGMT News
Valuation
SGMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
5.42x
SGMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGMT's financial health
Profit margin
Revenue
$2.0M
Net Income
-$6.4M
Profit Margin
-317.6%
Assets to liabilities
Assets
$102.9M
Liabilities
$5.1M
Debt to equity
0.05
SGMT's short-term assets ($102.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGMT's short-term assets ($102.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$0.0
Financing
$87.2M
SGMT vs Biotech Stocks
Sagimet Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.